Scientists And Public Officials Must Pursue Collaboration To Set Research Priorities

Should scientists assume responsibility for proposing a national agenda for science? It is not easy to take a stand against priority-setting and the kind of rational, systematic analysis the notion implies. But recent proposals that call on the scientific community to "get its act together" and unite behind a single set of research priorities raise serious doubts about its wisdom. At the same time, with scientists and policymakers increasingly concerned about how to find funds for the growing

Written byAlbert Teich
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Should scientists assume responsibility for proposing a national agenda for science? It is not easy to take a stand against priority-setting and the kind of rational, systematic analysis the notion implies. But recent proposals that call on the scientific community to "get its act together" and unite behind a single set of research priorities raise serious doubts about its wisdom.

At the same time, with scientists and policymakers increasingly concerned about how to find funds for the growing list of "megaprojects" begun by the Reagan administration, the business of setting priorities is becoming increasingly urgent. For example, presidential science adviser D. Allan Bromley has indicated that his office intends to establish a priority-setting process, and the Office of Management and Budget (OMB) is reported to be looking at research in a more comprehensive fashion than it ever has before.

Behind the various proposals that have been under discussion in science ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies